Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients

Medicina (Lithuania)

Volumn 53, Issue 2, 2017, Pages 90-100

  Petrulienė, Kristina ^a   Žiginskienė, Edita ^a   Kuzminskis, Vytautas ^a   Nedzelskienė, Irena ^a   Bumblytė, Inga Arūnė ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Erythropoiesis stimulating agents; Hepcidin; Inflammation; Renal anemia; Resistance

Indexed keywords

ANTIANEMIC AGENT; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; HEPCIDIN; RECOMBINANT PROTEIN;

AGED; BLOOD; DOSE RESPONSE; DRUG RESISTANCE; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEPCIDINS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 85017469517     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medici.2017.03.001     Document Type: Article

References (51)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group, KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2 (2012), 279–335.
2. Palmer, S.C., Navaneethan, S.D., Craig, J.C., Johnson, D.W., Tonelli, M., Garg, A.X., et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153:July (1) (2010), 23–33.
3. Gillespie, I.A., Macdougall, I.C., Richards, S., Jones, V., Marcelli, D., Froissart, M., et al. Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study. Pharmacoepidemiol Drug Saf 24:April (4) (2015), 414–426.
4. Canavesi, E., Alfieri, C., Pelusi, S., Valenti, L., Hepcidin and HFE protein: iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol 1:December (6) (2012), 166–176.
5. Valenti, L., Messa, P., Pelusi, S., Campostrini, N., Girelli, D., Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clin Chem Lab Med 52:May (5) (2014), 613–619.
6. Ganz, T., Hepcidin and iron regulation, 10 years later. Blood 117:April (17) (2011), 4425–4433.
7. Goodnough, L.T., Iron deficiency syndromes and iron-restricted erythropoiesis (CME). Transfusion 52:July (7) (2012), 1584–1592.
8. Kato, A., Tsuji, T., Luo, J., Sakao, Y., Yasuda, H., Hishida, A., Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 28:1 (2008), 115–121.
9. Kuragano, T., Shimonaka, Y., Kida, A., Furuta, M., Nanami, M., Otaki, Y., et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 31:6 (2010), 534–540.
10. Weiss, G., Theurl, I., Eder, S., Koppelstaetter, C., Kurz, K., Sonnweber, T., et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 39:October (10) (2009), 883–890.
11. van der Weerd, N.C., Grooteman, M.P., Bots, M.L., van den Dorpel, M.A., den Hoedt, C.H., Mazairac, A.H., et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS ONE, 7(7), 2012, e39783.
12. Ashby, D.R., Gale, D.P., Busbridge, M., Murphy, K.G., Duncan, N.D., Cairns, T.D., et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75:May (9) (2009), 976–981.
13. Nakanishi, T., Hasuike, Y., Otaki, Y., Kida, A., Nonoguchi, H., Kuragano, T., Hepcidin: another culprit for complications in patients with chronic kidney disease?. Nephrol Dial Transplant 26:October (10) (2011), 3092–3100.
14. van der Weerd, N.C., Grooteman, M.P., Nube, M.J., ter Wee, P.M., Swinkels, D.W., Gaillard, C.A., Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker. Neth J Med 73:March (3) (2015), 108–118.
15. van der Weerd, N.C., Grooteman, M.P., Bots, M.L., van den Dorpel, M.A., den Hoedt, C.H., Mazairac, A.H., et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 28:December (12) (2013), 3062–3071.
16. Fishbane, S., Mathew, A., Vaziri, N.D., Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant 29:February (2) (2014), 255–259.
17. Zumbrennen-Bullough, K., Babitt, J.L., The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 29:February (2) (2014), 263–273.
18. Lopez-Gomez, J.M., Portoles, J.M., Aljama, P., Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl(December (111)), 2008, S75–S81 doi(111):S75-81.
19. Vega, A., Ruiz, C., Abad, S., Quiroga, B., Velazquez, K., Yuste, C., et al. Body composition affects the response to erythropoiesis-stimulating agents in patients with chronic kidney disease in dialysis. Ren Fail 36:August (7) (2014), 1073–1077.
20. Ziginskiene, E., Kuzminskis, V., Petruliene, K., Vaiciuniene, R., Stankuviene, A., Bumblyte, I.A., Renal anemia control in Lithuania: influence of local conditions and local guidelines. Sci World J, 2013(December), 2013, 260915.
21. Wagner, M., Ashby, D., Hepcidin – a well-known iron biomarker with prognostic implications in chronic kidney disease. Nephrol Dial Transplant 28:December (12) (2013), 2936–2939.
22. Bradbury, B.D., Critchlow, C.W., Weir, M.R., Stewart, R., Krishnan, M., Hakim, R.H., Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 24:March (3) (2009), 919–925.
23. Rattanasompattikul, M., Molnar, M.Z., Zaritsky, J.J., Hatamizadeh, P., Jing, J., Norris, K.C., et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant 28:July (7) (2013), 1936–1945.
24. Valenti, L., Girelli, D., Valenti, G.F., Castagna, A., Como, G., Campostrini, N., et al. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol 4:August (8) (2009), 1331–1337.
25. Sany, D., Elsawy, A.E., Elshahawy, Y., Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 25:September (5) (2014), 967–973.
26. Coyne, D.W., Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 80:August (3) (2011), 240–244.
27. Swinkels, D.W., Wetzels, J.F., Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant 23:August (8) (2008), 2450–2453.
28. Costa, E., Swinkels, D.W., Laarakkers, C.M., Rocha-Pereira, P., Rocha, S., Reis, F., et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 122:4 (2009), 226–229.
29. Rostoker, G., Griuncelli, M., Loridon, C., Couprie, R., Benmaadi, A., Bounhiol, C., et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med, 125(October (10)), 2012 991–999.e1.
30. Rosati, A., Tetta, C., Merello, J.I., Palomares, I., Perez-Garcia, R., Maduell, F., et al. Cumulative iron dose and resistance to erythropoietin. J Nephrol 28:October (5) (2015), 603–613.
31. Tessitore, N., Girelli, D., Campostrini, N., Bedogna, V., Pietro Solero, G., Castagna, A., et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 25:December (12) (2010), 3996–4002.
32. do Sameiro-Faria, M., Ribeiro, S., Rocha-Pereira, P., Fernandes, J., Reis, F., Bronze-da-Rocha, E., et al. Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. Ren Fail 35:10 (2013), 1392–1398.
33. Neven, E., De Schutter, T.M., Behets, G.J., Gupta, A., D'Haese, P.C., Iron and vascular calcification. Is there a link?. Nephrol Dial Transplant 26:April (4) (2011), 1137–1145.
34. Pelusi, S., Girelli, D., Rametta, R., Campostrini, N., Alfieri, C., Traglia, M., et al. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol, 14(February), 2013 14:48-2369-14-48.
35. Rubab, Z., Amin, H., Abbas, K., Hussain, S., Ullah, M.I., Mohsin, S., Serum hepcidin levels in patients with end-stage renal disease on hemodialysis. Saudi J Kidney Dis Transpl 26:January (1) (2015), 19–25.
36. Kali, A., Yayar, O., Erdogan, B., Eser, B., Buyukbakkal, M., Ercan, Z., et al. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients?. Hemodial Int 20:April (2) (2016), 191–197.
37. Kotanko, P., Thijssen, S., Levin, N.W., Association between erythropoietin responsiveness and body composition in dialysis patients. Blood Purif 26:1 (2008), 82–89.
38. Kanbay, M., Perazella, M.A., Kasapoglu, B., Koroglu, M., Covic, A., Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 29:1 (2010), 1–12.
39. Movilli, E., Cancarini, G.C., Zani, R., Camerini, C., Sandrini, M., Maiorca, R., Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 16:January (1) (2001), 111–114.
40. Movilli, E., Cancarini, G.C., Vizzardi, V., Camerini, C., Brunori, G., Cassamali, S., et al. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores. J Nephrol 16:July–August (4) (2003), 546–551.
41. Green, D., Kalra, P.R., Kalra, P.A., Echocardiographic abnormalities in dialysis patients with normal ejection fraction. Nephrol Dial Transplant 27:December (12) (2012), 4256–4259.
42. Kainz, A., Mayer, B., Kramar, R., Oberbauer, R., Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant 25:November (11) (2010), 3701–3706.
43. Panichi, V., Rosati, A., Bigazzi, R., Paoletti, S., Mantuano, E., Beati, S., et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 26:August (8) (2011), 2641–2648.
44. Okazaki, M., Komatsu, M., Kawaguchi, H., Tsuchiya, K., Nitta, K., Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif 37:2 (2014), 106–112.
45. Vaiciuniene, R., Evaluation of predisposing factors for hospitalization in hemodialysis patients. (Doctorial dissertation: biomedical sciences, medicine), 2010, Lithuanian University of Health Sciences.
46. Saeed, O., Otsuka, F., Polavarapu, R., Karmali, V., Weiss, D., Davis, T., et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 32:February (2) (2012), 299–307.
47. Kuragano, T., Itoh, K., Shimonaka, Y., Kida, A., Furuta, M., Kitamura, R., et al. Hepcidin as well as TNF-alpha are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 26:August (8) (2011), 2663–2667.
48. Gaweda, A.E., Ginzburg, Y.Z., Chait, Y., Germain, M.J., Aronoff, G.R., Rachmilewitz, E., Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant 30:February (2) (2015), 187–196.
49. Sun, C.C., Vaja, V., Babitt, J.L., Lin, H.Y., Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 87:April (4) (2012), 392–400.
50. Nemeth, E., Anti-hepcidin therapy for iron-restricted anemias. Blood 122:October (17) (2013), 2929–2931.
51. Bonomini, M., Del Vecchio, L., Sirolli, V., Locatelli, F., New treatment approaches for the anemia of CKD. Am J Kidney Dis 67:January (1) (2016), 133–142.